Columbia Laboratories, Inc. (NasdaqCM:CBRX) received notice on August
23, 2012, from the Nasdaq Stock Market that the Company has regained
compliance with the Nasdaq Stock Market minimum bid price requirement as
set forth in Listing Rule 5550(a)(2). The notice stated that the closing
bid price of the Company's common stock has been at $1.00 per share or
greater for the previous ten consecutive business days.
About Columbia Laboratories
Columbia Laboratories, Inc. is a publicly traded specialty
pharmaceutical company with a successful history of developing
proprietary, vaginally administered products for women’s health
indications. For more information, please visit www.columbialabs.com.
Copyright Business Wire 2013